![Jak na přijímačky](https://cdn.muni.cz/media/3633702/image_1.jpg?mode=crop¢er=0.5,0.5&rnd=133572412150000000&heightratio=0.5&width=278)
Informace o publikaci
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Autoři | |
---|---|
Rok publikování | 2014 |
Druh | Článek v odborném periodiku |
Časopis / Zdroj | The Lancet |
Citace | |
Obor | Onkologie a hematologie |
Popis | Ramucirumab is the first biological treatment given as a single drug that has survival benefits in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma progressing after first-line chemotherapy. Our findings validate VEGFR-2 signalling as an important therapeutic target in advanced gastric cancer. |